ERBB2 and neoplasm: Since the biodistribution of [111In]In-DTPA-trastuzumab was extensively determined previously in HER2-positive tumor-bearing mice, with the most pronounced uptake 2 days after injection [21], our biodistribution and imaging experiments were performed at one time point.